Atea Pharmaceuticals Inc Asset Resilience Ratio
Atea Pharmaceuticals Inc asset resilience ratio. Atea Pharmaceuticals Inc (AVIR) has an Asset Resilience Ratio of 61.53% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Atea Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Atea Pharmaceuticals Inc (2021–2025)
Asset resilience ratio of Atea Pharmaceuticals Inc from 2021 to 2025. This chart shows how Atea Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read debt load of Atea Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Atea Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Atea Pharmaceuticals Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $142.92 Million | 61.53% |
| Total Liquid Assets | $142.92 Million | 61.53% |
Asset Resilience Insights
- Very High Liquidity: Atea Pharmaceuticals Inc maintains exceptional liquid asset reserves at 61.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Atea Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Atea Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Atea Pharmaceuticals Inc Asset Resilience Ratio by Year (2021–2025)
Atea Pharmaceuticals Inc asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Atea Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 65.39% | $206.12 Million | $315.22 Million | -18.55pp |
| 2024-12-31 | 83.94% | $390.02 Million | $464.67 Million | +10.94pp |
| 2023-12-31 | 72.99% | $434.28 Million | $594.97 Million | +4.26pp |
| 2022-12-31 | 68.73% | $458.25 Million | $666.71 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $772.89 Million | -- |
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company … Read more